samedan logo
 
 
spacer
home > pmps > winter 2020 > a new era for packaging technologies
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

A New Era for Packaging Technologies





Decision makers in the pharmaceutical industry face a complicated marketplace. Often, they are procuring solutions that need to meet a bespoke set of challenges for their own particular application. They may also need machines from a variety of suppliers, or at least face a variety of options for which equipment manufacturer and technology platform to use. They may well need to consider interoperability with existing plants, are likely to have one eye on security, compliance, and serialisation, and may have any number of other considerations on their mind, such as improving performance, flexibility, connectivity, or efficiency.

Pharma packaging is a rapidly growing global industry as well. As of 2019, it is estimated to be worth around $86.3 billion and is set to grow to almost $112 billion by 2024. Driving the growth are a variety of factors, from supplying emerging economies to new drug developments such as nanotechnology and nanomedicines.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Experienced in the development and implementation of industry strategies, Andrew Smith has held several customer-focused positions throughout his 12-year career with Rockwell Automation. Having previously been responsible for strategy and growth of architecture and software products in the Nordic Region, Andrew is now the EMEA Sector Lead for Process and Packaging OEMs where his insights and experience are helping the biggest names in the industry overcome the challenges they face.
Print this page
Send to a friend
Privacy statement
News and Press Releases

ICON Releases Environmental, Social and Governance Report

ICON announced today the release of its 2020 Environmental, Social and Governance (ESG) Report.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement